Is Zepbound approved for sleep apnea?

Yes. It is approved in the US and, since the June 2026 Canadian monograph, in Canada for moderate to severe obstructive sleep apnea in adults with obesity.

How much did Zepbound improve sleep apnea in trials?

In SURMOUNT-OSA, average breathing interruptions per hour fell by about 25 to 29 on Zepbound vs about 5 on placebo at 52 weeks, and 61% to 72% of people on Zepbound cut their AHI by at least half vs about 19% to 23% on placebo.

Does Zepbound replace a CPAP machine?

No. The Canadian monograph says it is not a replacement for positive airway pressure in people who need it. A sleep specialist or prescriber decides how therapies combine.

Is Mounjaro approved for sleep apnea?

No. Mounjaro is tirzepatide for type 2 diabetes. The sleep-apnea indication is on the Zepbound brand.

Does Zepbound cause insomnia?

Insomnia is not a listed side effect. Some users report poor sleep for other reasons. See GLP-1 insomnia and sleep.

Zepbound for Sleep Apnea: SURMOUNT-OSA Results, US and Canada Approvals

Zepbound for sleep apnea: SURMOUNT-OSA trial results, US and Canada approvals, who it is for, and how it relates to insomnia reports. Not medical advice.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Zepbound (tirzepatide) is approved to treat moderate to severe obstructive sleep apnea in adults with obesity, in addition to its weight-management use. The approval rests on the two 52-week SURMOUNT-OSA trials published in the New England Journal of Medicine in 2024: average breathing interruptions per hour fell by about 25 to 29 on Zepbound vs about 5 on placebo, and many more people cut their apnea events by at least half. The US label and the Canadian Zepbound monograph (June 11, 2026) both list this use. Zepbound is not a substitute for CPAP or other positive airway pressure if someone still needs it. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Last reviewed November 7, 2026.

What SURMOUNT-OSA showed

Two parallel trials enrolled adults with obesity and moderate to severe obstructive sleep apnea. SURMOUNT-OSA-1 studied people not using CPAP or other positive airway pressure; SURMOUNT-OSA-2 studied people who were. Both ran for 52 weeks. Figures below match Table 14 of the Canadian monograph (and the published NEJM results).

At 52 weeks	SURMOUNT-OSA-1: Zepbound vs placebo	SURMOUNT-OSA-2: Zepbound vs placebo
Change in breathing interruptions per hour (AHI)	−25.3 vs −5.3	−29.3 vs −5.5
Percent change in AHI	−50.7% vs −3.0%	−58.7% vs −2.5%
People with at least a 50% drop in AHI	61.2% vs 19.0%	72.4% vs 23.3%

Who the indication covers

Both the US Zepbound label and the Canadian monograph describe moderate to severe obstructive sleep apnea in adults with obesity. Sleep apnea is a medical diagnosis (loud snoring, gasping, pauses in breathing and daytime sleepiness are reasons to ask about a sleep study). Mounjaro is the same molecule for type 2 diabetes and does not carry this sleep-apnea indication. Overview: Mounjaro vs Zepbound and Zepbound in Canada.

Side effects in the sleep apnea trials

In SURMOUNT-OSA-1 and -2 (467 adults treated), side effects were similar to the weight-management trials: mainly gastrointestinal reactions while the dose was increased. Full rates: Zepbound side effects. The monograph says Zepbound is not a replacement for positive airway pressure in people who need it.

Sleep apnea vs insomnia on a GLP-1

These are different problems. Sleep apnea is interrupted breathing during sleep; insomnia is trouble falling or staying asleep. Insomnia is not listed as a side effect on the Zepbound, Mounjaro, Wegovy or Ozempic labels, though some users still report poor sleep from reflux, burping, hunger or a faster heart rate. Detail: GLP-1 insomnia and sleep.

What users report here

Few confessions name a formal sleep-apnea diagnosis. On tirzepatide, #774 says GLP-1s made their CPAP redundant, but late dinners still meant burps waking them at night. Other sleep stories on this site are mostly about insomnia on investigational retatrutide, not approved Zepbound for OSA. Stories, not rates. Side-effect counts: tirzepatide side-effects report.

More confessions from the archive

Community Q&A

Is Zepbound approved for sleep apnea?: Yes. It is approved in the US and, since the June 2026 Canadian monograph, in Canada for moderate to severe obstructive sleep apnea in adults with obesity.
How much did Zepbound improve sleep apnea in trials?: In SURMOUNT-OSA, average breathing interruptions per hour fell by about 25 to 29 on Zepbound vs about 5 on placebo at 52 weeks, and 61% to 72% of people on Zepbound cut their AHI by at least half vs about 19% to 23% on placebo.
Does Zepbound replace a CPAP machine?: No. The Canadian monograph says it is not a replacement for positive airway pressure in people who need it. A sleep specialist or prescriber decides how therapies combine.
Is Mounjaro approved for sleep apnea?: No. Mounjaro is tirzepatide for type 2 diabetes. The sleep-apnea indication is on the Zepbound brand.
Does Zepbound cause insomnia?: Insomnia is not a listed side effect. Some users report poor sleep for other reasons. See GLP-1 insomnia and sleep.
Does this page give dosing advice?: Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Sources

Last reviewed November 7, 2026. Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.